Prenylcysteine oxidase 1 like (PCYOX1L)

Prenylcysteine oxidase 1 like (PCYOX1L) is an enzyme-coding gene/product with predicted oxidoreductase activity, specifically acting on sulfur-containing groups with oxygen as acceptor[3][5]. It participates in the degradation of prenylated proteins, a process crucial for cellular viability and the metabolic mevalonate pathway[6]. PCYOX1L is required for proper protein prenylation, and its loss impairs autophagy, reduces viability under homeostatic conditions, and hinders the bactericidal properties of neutrophils[6]. While PCYOX1 (the paralog) is established as a contributor to lipoprotein oxidation and atherogenesis[1], the direct therapeutic relevance or drug interactions of PCYOX1L remain uncharacterized. PCYOX1L is primarily membrane-associated[2], with significant evolutionary conservation between human and mouse orthologs, reflecting likely essential functions in innate immunity and metabolic regulation[6]. Genetic variation in PCYOX1L is linked with cerebral amyloid angiopathy, but causal mechanisms are undefined[5]. Currently, PCYOX1L is not considered an established therapeutic target, and there are no known drugs or clinical safety concerns associated with inhibiting or modulating its activity.

Other names

PCYOX1Lprenylcysteine oxidase 1-likeprenylcysteine oxidase-likePSEC0105MGC3265